Results 141 to 150 of about 304,614 (388)
Rheumatology, 2006 Secondary Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc) and other collagen vascular diseases is a serious manifestation of microvascular damage that may precede the onset of visceral and/or cutaneous sclerosis for years.
N. Selenko-Gebauer +4 more
semanticscholar +1 more source
Growth factors in idiopathic pulmonary fibrosis: relative roles [PDF]
, 2001 Treatment of idiopathic pulmonary fibrosis patients has evolved very slowly; the fundamental approach of corticosteroids alone or in combination with other immunosuppressive agents has had little impact on long-term survival.
Allen, JT, Spiteri, MA
core +3 more sources
Evidence for biased agonists and antagonists at the endothelin receptors
Life Sciences, 2016 Biased ligands represent a new strategy for the development of more effective and better tolerated drugs. To date there has been a paucity of research exploring the potential of ligands that exhibit either G protein or β-arrestin pathway selectivity at the endothelin receptors.
openaire +3 more sources
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. [PDF]
Cardiovasc Diabetol, 2023 Smeijer JD +9 more
europepmc +1 more source
Pharmacotherapy for Cirrhosis in Japan
Portal Hypertension &Cirrhosis, EarlyView.As cirrhosis progresses from the compensated to the decompensated stage, liver disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, and bleeding tendency, as well as liver carcinogenesis, can occur at a high rate. With the advent of new pharmacotherapies for cirrhosis in the last decade, liver fibrosis has been shown ...
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
wiley +1 more source
Current status of bosentan for treatment of pulmonary hypertension
Annals of Cardiac Anaesthesia, 2008 Pulmonary arterial hypertension (PAH) is a debilitating disease associated with significant morbidity and a high mortality if left untreated. Over the past 5 years, there have been significant advances with regard to the understanding of the pathogenesis,
Raja Shahzad, Dreyfus Gilles
doaj
The use of Macitentan in Fontan circulation: a case report
BMC Cardiovascular Disorders, 2017 Background The Fontan circulation, a result of a palliative procedure in patients with single systemic ventricles, is defined by chronically elevated pulmonary vascular resistance.
Polyvios Demetriades +4 more
doaj +1 more source
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. [PDF]
Sci Rep, 2022 Fontes MSC +4 more
europepmc +1 more source
Endothelin receptor antagonists in pulmonary arterial hypertension
Journal of the American College of Cardiology, 2004 Endothelin receptor antagonism has emerged as an important therapeutic strategy in pulmonary arterial hypertension (PAH). Laboratory and clinical investigations have clearly shown that endothelin (ET)-1 is overexpressed in several forms of pulmonary vascular disease and likely plays a significant pathogenetic role in the development and progression of ...
Robyn J. Barst +4 more
openaire +3 more sources
British Journal of Clinical Pharmacology, EarlyView.Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post +4 more
wiley +1 more source